durvalumab,sorafenib,tremelimumab
astrazeneca,pfizer
['himalaya']
#asco23: in himalaya, most immune mediated adverse events in the stride arm occurred during the first 3 months and patients who experienced them had better survival. not clear how imaes were managed nor whether severity influenced survival. 
Med Onc, Director GI Oncology @ProvHealth @ChilesResearch, Co-chair SWOG Rectal-Anal Cmmtee, NCI GSC Member, #colorectalcancer #NETs. Cycling & ski enthusiast!